Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy

International Journal of Hematology

Volumn 96, Issue 6, 2012, Pages 743-747

  McLaughlin, Brian ^a   Im, Annie ^a   Raptis, Anastasios ^a   Agha, Mounzer ^a   Hou, Jing Zhou ^a   Redner, Robert ^a   Duggal, Shrina ^a   Lin, Yan ^a   Smith, Clay ^a   Boyiadzis, Michael ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Cytarabine; Fludarabine; Relapse leukemia

Indexed keywords

CLOFARABINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; PENTAMIDINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLITIS; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK POPULATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; LUNG MYCOSIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PNEUMOCYSTIS JIROVECI; PNEUMONIA; REPEAT PROCEDURE; RESPIRATORY FAILURE; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TYPHLITIS; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; GASTROINTESTINAL DISEASE; GENETICS; HEMATOLOGIC DISEASE; KARYOTYPE; MIDDLE AGED; RECURRENT DISEASE; REMISSION; SECOND CANCER; TOXIC HEPATITIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DRUG-INDUCED LIVER INJURY; ETOPOSIDE; FEMALE; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASMS, SECOND PRIMARY; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; VIDARABINE;

EID: 84875257410     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1192-9     Document Type: Article

References (18)

1. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116:3147-56.
2. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29:487-94.
3. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood. 2011;117:2307-18.
4. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.
5. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-7. (Pubitemid 26068888)
6. Capizzi RL. Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside. Invest New Drugs. 1996;14:249-56. (Pubitemid 26383938)
7. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903. (Pubitemid 24299870)
8. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116-24. (Pubitemid 23059984)
9. Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9:343-50. (Pubitemid 23209513)
10. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol. 1994;12:671-8.
11. Vidarsson B, Abonour R, Williams EC, et al. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia. Leuk Lymphoma. 2001;41:321-31. (Pubitemid 32499414)
12. Mehta DR, Foon KA, Redner RL, et al. Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. Leuk Res. 2011;35:885-8.
13. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-36. (Pubitemid 35429670)
14. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-83.
15. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-9. (Pubitemid 46594039)
16. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969-78. (Pubitemid 46211376)
17. Giles F, O'Brien S, Cortes J, et al. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005;104:547-54. (Pubitemid 41022812)
18. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma. 2002;43:1715-27. (Pubitemid 34874002)